Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.78 USD
Change Today +0.21 / 8.17%
Volume 100.3K
GALT On Other Exchanges
Symbol
Exchange
NASDAQ CM
NASDAQ CM
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

Audit Committee* - galectin therapeutics inc (GALT)

Name (Connections)Board RelationshipsTitleKey Developments
Steven Prelack 13 RelationshipsDirector and Chairman of Audit CommitteeGalectin Therapeutics, Inc. announced delayed annual 10-K filing
03/16/15
Arthur Greenberg 9 RelationshipsDirector, Member of Audit Committee and Member of Nominating & Corporate Governance CommitteePro-Pharmaceuticals Inc. announced delayed 10-Q filing
05/15/06
Kevin Freeman CFA 9 RelationshipsDirector and Member of Audit CommitteePro-Pharmaceuticals Inc. announced delayed annual 10-K filing
04/1/05

Compensation Committee* - galectin therapeutics inc (GALT)

Name (Connections)Board RelationshipsTitle
Gilbert Omenn M.D., Ph.D. 152 RelationshipsDirector and Chairman of Compensation Committee
Marc Rubin M.D. 28 RelationshipsLead Independent Director and Member of Compensation Committee
GALT Compensation vs. Industry
485.0K
363.5K
Chief Executive Officer
175.0K
265.1K
Chief Financial Officer
230.0K
347.3K
Chief Operating Officer
Share price activity for GALECTIN THERAPEUTICS INC (GALT)
52 Week Price Performance
GALT
Industry Average

Nominating Committee* - galectin therapeutics inc (GALT)

Name (Connections)Board RelationshipsTitleKey Developments
Arthur Greenberg 9 RelationshipsDirector, Member of Audit Committee and Member of Nominating & Corporate Governance CommitteeGalectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development
07/15/15
John Mauldin 21 RelationshipsDirector and Member of Nominating & Corporate Governance CommitteeGalectin Therapeutics Names Dr. Marc Rubin as Lead Independent Director
06/3/15

Corporate Governance Committee* - galectin therapeutics inc (GALT)

Name (Connections)Board RelationshipsTitle
Arthur Greenberg 9 RelationshipsDirector and Chairman of Compensation Committee
John Mauldin 21 RelationshipsLead Independent Director and Member of Compensation Committee
GALT and Competitor
Insiders vs. External
Board
20%
80%
Galectin Therapeutics, Inc.
Insiders
External Board Members

Advisory Committee* - galectin therapeutics inc (GALT)

Name (Board Relationships)/Title Board Affiliations
Anatole Klyosov 9 Relationships
Co-founder and Member of The Scientific Board
No other board affiliations
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALT:US $2.78 USD +0.21

GALT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GALT.
View Industry Companies
 

Industry Analysis

GALT

Industry Average

Valuation GALT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALECTIN THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.